Keros Therapeutics (KROS)
NASDAQ:KROS
Want to see KROS full AI Analyst Report?
KROS Stock Chart & Stats
$11.67
-$0.58(-3.66%)
At close: 4:00 PM EST
$11.67
-$0.58(-3.66%)
Day’s Range― - ―
52-Week Range$10.42 - $22.55
Previous CloseN/A
Volume109.28K
Average Volume (3M)491.06K
Market Cap
$230.33M
Enterprise Value$178.73M
Total Cash (Recent Filing)$287.42M
Total Debt (Recent Filing)$16.88M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.86
Shares Outstanding19,787,836
10 Day Avg. Volume348,824
30 Day Avg. Volume491,060
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.50
Price to Sales (P/S)3.11
P/FCF Ratio7.15
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue0.73
Enterprise Value/Gross Profit0.74
Enterprise Value/Ebitda2.16
Forecast
1Y Price Target
$22.17Price Target Upside89.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-4.89
Revenue Forecast (FY)$10.29M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsEarly human results showing increases in lean body mass, thigh muscle volume and improvements in bone markers support the drug's mechanism and suggest potential functional benefits in neuromuscular diseases.
Partnerships And Resource FocusAn exclusive global partnership and a collaboration with Takeda provide external funding and permit concentration of company resources on advancing rinvatercept into neuromuscular indications.
Safety Profile AdvantageReduced binding to the protein previously linked to bleeding in earlier activin receptor therapies suggests a potentially more favorable safety profile that could ease regulatory and clinical development hurdles.
Bears Say
Safety Signal — Hemoglobin IncreasesDose-dependent hemoglobin increases observed in early studies have led to dose reductions and raise tolerability concerns that may require additional safety monitoring or impact dosing strategy.
Study Design And Sample Size LimitationsThe planned Phase 2 open-label basket study with limited enrollment may produce inconclusive efficacy signals and necessitate larger trials to confirm benefit.
Trial Delays And Regulatory UncertaintyDelay of the Phase 2 Duchenne trial and unclear FDA input on study design create regulatory uncertainty that can slow clinical momentum and weigh on investor confidence.
Keros Therapeutics News
KROS FAQ
What was Keros Therapeutics’s price range in the past 12 months?
Keros Therapeutics lowest stock price was $10.41 and its highest was $22.55 in the past 12 months.
What is Keros Therapeutics’s market cap?
Keros Therapeutics’s market cap is $230.33M.
When is Keros Therapeutics’s upcoming earnings report date?
Keros Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 95 days.
How were Keros Therapeutics’s earnings last quarter?
Currently, no data Available
Is Keros Therapeutics overvalued?
According to Wall Street analysts Keros Therapeutics’s price is currently Undervalued.
Does Keros Therapeutics pay dividends?
Keros Therapeutics does not currently pay dividends.
What is Keros Therapeutics’s EPS estimate?
Keros Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Keros Therapeutics have?
Keros Therapeutics has 19,787,836 shares outstanding.
What happened to Keros Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Keros Therapeutics?
Currently, no hedge funds are holding shares in KROS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Keros Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.17 (89.95% Upside)
$22.17 (89.95% Upside)
Blogger Sentiment
Bullish
KROS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $254.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.05%
12-Months-Change
Fundamentals
Return on Equity
14.25%
Trailing 12-Months
Asset Growth
-44.33%
Trailing 12-Months
Company Description
Keros Therapeutics
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
KROS Stock 12 Month Forecast
Average Price Target
$22.17
▲(89.95% Upside)
Technical Analysis
Gyre Therapeutics
―
KalVista Pharmaceuticals
―
Palvella Therapeutics
―
Nurix Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
50.90% Insiders
18.49% Mutual Funds
0.87% Other Institutional Investors
13.45% Public Companies and
Individual Investors